Although two recent studies have failed to reveal lipoprotein(a) (LP(a)) serum concentrations > 300 mg/1 to be an independent risk factor for early onset of atherosclerosis, Lp(a) serum concentrations are frequently measured to evaluate the additional risk of coronary heart disease. We describe a time-resolved immunofluorometric assay (TRIFMA) for quantifying Lp(a) levels in human serum using commercially available reagents, which is rapid, robust and simple to perform. The two-site immunometric assay was based on microtitre plates as solid phase coated with a polycloncal anti Lp(a) antibody. The liquid-phase antibody was labelled with biotin and detected by europium labelled streptavidin in the DELFIA 1232 fluorometer. The measuring range was 2-1600 mg/1. The intra-assay imprecision was < 7% (CV), the inter-assay imprecision < 12% (CV). No interference was detected with plasminogen concentrations up to 2.2 g/1. There was an acceptable correlation with a commercially available enzyme immunoassay (r = 0.95) and with electroimmunodiffiision (r = 0.85) on 100 routine serum samples measured. The assay appeared to detect different Lp(a) isoforms as dilution curves were parallel for B/F, S 2 and S 4 isoforms.
Introduction
Numerous epidemiological and case-control studies have revealed lipoprotein(a) (Lp(a)) serum concentrations > 300 mg/1 to be an independent risk factor for myocardial infarction, stroke and restenosis after coronary artery bypass surgery (1) (2) (3) (4) (5) (6) (7) (8) (9) . The results have been confirmed by a prospective study (10) . Ridker et al. and Jauhiainen et al., however, could not show any correlation between Lp(a) serum levels and atherosclerosis (11, 12) . Nevertheless, Lp(a) serum concentrations are frequently measured to estimate the additional risk of atherosclerotic disease.
Lp(a) 1 ) is a cholesterol ester-rich lipoprotein which resembles LDL 1 ) with the presence of apolipoprotein B* ) Non-standard abbreviations: Lp(a): h'poprotein(a); TRIFMA: time-resolved immunofluorometric assay; LDL: low density lipoprotein; IRMA: immunoradiometric assay; EIA: enzyme immunoassay; IEMA: immunoenzymometric assay. 100 to which the glycoprotein apolipoprotein(a) is covalently bound. Apolipoprotein(a) contains three structural regions, which are also present in plasminogen: variable numbers of kringle 4, one kringle 5 and a protease domain (14) . The number of kringle 4 repeats is a genetic trait and determines the relative molecular mass ( ) polymorphism of apolipoprotein(a). In the Caucasian population the frequency distribution of Lp(a) serum concentration is markedly skewed with a shift toward lower levels. Lp(a) serum concentrations are inversely related to the size of apolipoprotein(a) isoforms and range from less than 1 mg/1 to > 2000 mg/1 (9) .
Several analytical methods have been described to quantify Lp(a) levels in serum. Electroimmunodiffusion (EID) was followed by radioimmunoassay (RIA) and enzyme immunoassay (EIA) (16) (17) (18) (19) (20) . Nephelometric techniques have recently been introduced to automate the Lp(a) determination (21, 22) . These methods, however, are either difficult to perform in large series, time consuming, or lack accuracy and precision at low and high concentrations of Lp(a). The use of radioimmunoassays is restricted to authorised laboratories.
We describe a non-radioisotopic Lp(a) assay, which offers a wide measuring range, high sensitivity and low intra-and inter-assay imprecision. The assay is rapid, robust, simple to perform and suitable for routine use.
Materials and Methods

Samples
Serum was used as specimen throughout. The sera were measured either directly after centrifugation or after being stored frozen at -20 °C. Samples to define the reference range were obtained from healthy blood donors. The plasma and serum samples for the comparison of measurement in plasma and serum were obtained from healthy employees of the hospital. many), and the DELFIA 1232 time-resolved fluorometer from Pharmacia (Uppsala, Sweden).
Assay procedure
Microtitre plates were coated with 200 μΐ per well of sheep anti Lp(a) antibody from Immuno (10 μΐ diluted in 20ml coating buffer). Each plate was allowed to stand 'oVernight at 4 °C, then the coating solution was aspirated, the plate washed once with washing buffer, and 200 μΐ per well of assay buffer were added for storage.
Calibrators, controls and samples were diluted 1 :500 in assay buffer. The calibrator containing 800 mg/1 Lp(a) was diluted 1 :250 to give a final concentration of 1600 mg/I. Twenty μΐ of the diluted calibrators, controls and samples were pipetted into each well, allowed to stand for 30 minutes at ambient temperature (18-22 °C) followed by 200 μΐ assay buffer. After incubation for one hour on the microtitre plate shaker with 200 min"" 1 at ambient temperature, the plate was washed three times with washing buffer.
Reagents
All chemicals were analytical grade from Merck (Darmstadt, Germany) or Sigma (Deisenhofen, Germany), if not stated otherwise. We used double distilled water for all buffers and solutions.
Buffers
Assay buffer
Tris 0.05 mol/1, NaCl 0.15 mol/1, bovine serum albumin 5 g/1 (Sigma), bovine γ-globulin 0.5 g/1 (Sigma), diethylenetriaminepentaacetic acid (DTPA) 0.01 mol/1 (Sigma), NaN 3 0.15 mmol/1, Tween 20 0.2 ml/1 (Sigma), pH adjusted to 7.75.
Washing buffer
Tris 0.05 mol/1, NaCl 0.15 mol/1, Tween 20 l ml/l, pH 7.5. The washing buffer was stored in a 40-fold concentrate and was stable for half a year. 
Coating buffer
Enhancement solution
Citric acid 0.1 mol/1, tri-n-octyl-phosphine-oxide 0.01 mol/1, potassium-phthalate 0.08 mol/1 (Sigma), thenoyltrifluoroacetone 0.01 mol/1 (Sigma), Triton X-100 2 ml/1 (Sigma).
Antibodies
The Two-hundred μΐ of DAKO anti Lp(a) antibody which had been labelled with biotin as described previously (26) and diluted in assay buffer to a final concentration of 1 mg/1 were incubated for another hour (ambient temperature, 200 min~l). After washing three times with washing buffer, 200 μΐ of the streptavidin europium conjugate in assay buffer were added to each well and incubated for 30 minutes (ambient temperature, 200 min"" 1 ). Streptavidin was labelled as recommended by Pharmacia (Uppsala, Sweden) using their europium labelling reagent and diluted to a final concentration of 0.025 mg/1. After a final washing step 200 μΐ enhancement solution were added to each well and then incubated for 30 minutes (ambient temperature, 200 min" 1 ). The plate was measured in the DELFIA 1232 fluorometer. The calibration curve was constructed using a modified spline function in the FIA-Calc data reduction programme of the DELFIA 1232 system after a log/ log transformation of the data.
Tab. 3 Lp(a) levels in serum, heparin-, citrate-and EDTA-plasma of 20 healthy hospital employees. The coefficients of correlation for serum vs. citrate-plasma was r = 0.994, for serum vs. heparinized plasma r = 0.998, for serum vs. EDTA-plasma r = 0.999, respectively. (* Dilution effect of 1 : 10 must be taken into consideration. These were the measured concentrations.) Influence of haemolysis
To investigate the influence of haemolysis 10 blood samples were divided into two aliquots each. One was immediately centrifuged and the serum measured. The other was mechanically haemolysed on a tube shaker. All samples were macroscopically haemolytic after this procedure. The haemoglobin concentration after centrifugation was between 1 and 2 g/1, as measured with the cyanmethaemoglobin method (tab. 1).
Tab. Tab 
Interference of plasminogen
To assess the interference of plasminogen on the assay purified plasminogen (Sigma) was diluted in assay buffer to give final concentrations of 0.1; 2.2; 22; 220 and 2200 mg/1, respectively and measured in the assay. All concentrations were below the lowest calibrator (0.06; 0.26; 1.1; 0.6 and 1.4 mg/1, respectively). Even when measured without the obligate predilution corresponding to a theoretical, original concentration of 1100 g/l(!) only 16 mg/1 were detected.
Measurement in serum and different kinds of plasma
To evaluate the effect of measuring Lp(a) in different derivatives from blood, blood from 20 healthy employees of the hospital was obtained as serum, heparinized plasma, EDTA-plasma and citrateplasma. Results are given in table 3.
Effect of storing conditions on Lp(a) levels
To assess the influence of storing conditions on the stability of Lp(a) 10 serum samples were stored at 4 °C and -20 °C for 21 days. Another 10 samples were stored at 4 °C and -80 °C for the same period (tab. 4). The effect of repeated freeze and thaw cycles was not investigated, because the negative influence is well known.
Stability of coated microtitre plates
To evaluate the stability of the coated microtitre plates one plate was stored for 13 weeks in assay buffer at 4 °C and compared with a plate coated one week before (tab. 5).
Electroimmunodiffusion (EID)
Electroimmunodiffusion was performed in a 1 mm, anti Lp(a) antiserum containing agarose gel with a LKB-Multiphor II electrophoresis unit (LKB-Pharmacia, Uppsala, Sweden) as described recently (16, 23) .
Enzyme immunoassay (EIA)
To quantify Lp(a) by EIA, the IMMUNOZYM Lp(a) EIA kit from Immuno GmbH (Heidelberg, Germany) was used following the manufacturers recommendations. This kit uses a monospecific, polyclonal anti apolipoprotein(a) antibody on the solid-phase, and a peroxidase labelled, monoclonal anti apolipoprotein(a) antibody for detection (figs. 3 and 4).
Influence of apolipoprotein(a) isoforms on Lp(a) measurement
To investigate, whether the TRIFMA measures irrespective of different isoforms of apolipoprotein(a), sera containing apolipoprotein(a) isoforms B/F, 82 and 84 (determined as described by Laemmli (29)) were measured after serial dilution in assay buffer (Fig. 5 ).
Measurement in triacylglycerol-rich fraction
To test Lp(a) measurement in triacylglycerol-rich fraction of serum, sera were ultracentrifuged at 30000 min"" 1 for 18 hours and Tab. 7 Intra-assay TRIFMA. the supernatant and the remaining serum fraction measured separately after serial dilution in assay buffer ( fig. 6 ).
Statistical analyses
The correlation of Lp(a) levels between TRIFMA, BID and EIA, was calculated using a non-parametric linear regression analysis as described by Passing & Bablock (30) . In the legends to the figures 2, 3 and 4 the coefficient of correlation (r), the equation formula of the regression analysis (y = a + bx), the result of the Cusum test for deviation from linearity (significant or not significant) and the result of the test for contingency (p-values) are-given. To prove the data in tables 1, 3 and 4 statistically, the coefficient of correlation was calculated, instead of a statistical test, because of the low number of data pairs.
Results
Assay characteristics Figure 1 shows a typical calibration curve for the Lp(a) TRIFMA. The potential lower detection limit was 0.39 mg/1, calculated as the response of the zero calibrator (assay buffer) + 3 SD (n = 20). The measuring range was 2-1600 mg/1. A high dose "hook" effect was not detectable up to 5000 mg/1 (response for the 1600 mg/1 calibrator: 1 014527 counts/s, response for 5000 mg/1: 1 689 754 counts/s). Analytical recovery ranged from 87 to 108% (tab. 6). The intra-assay imprecision was < 7% (CV, n = 20), the inter-assay imprecision was < 12% (CV, n = 22) (tab. 7).
To calculate the reference range of Lp(a) in this assay, specimens from 88 healthy blood donors were measured. There is a wide range of Lp(a) levels in healthy individuals which does not follow a Gaussian distribution, as previously described (13 1 and 2) .
The Lp(a) TRIFMA was compared with the EIA from Immuno and the electroimmunodiffiision technique. The results of the TRIFMA correlated highly with the EIA (r = 0.95; y = 1.47 χ + 7.66, Cusum test on deviation from linearity: not significant, test for contingency: ρ = 0.003, η = 100; fig. 2 ). Differences were seen in low (< 40 mg/1) and high concentrations (> 450 mg/1). The correlation between the results of the TRIFMA and the electroimmunodiffiision assay (EID) was not as good as the latter, probably because of the better linearity of the TRIFMA over a wide measuring range (r = 0.85; y = 1.38 χ -69.7; Cusum test on deviation from linearity: not significant, test for contingency: p = 0.308, n = 100; fig. 3 ). This conjecture is supported by the better correlation between EIA and EID (r = 0.92; y = 0.98 χ -61.6; Cusum test on deviation from linearity: not significant, test for contingency: p = 0.065, n= 100; fig. 4 ). supernatant and the remaining fluid after ultracentrifugation is shown in figure 6 .
Discussion
Numerous investigations have revealed Lp(a) to be a genetically determined, independent risk factor for coronary heart disease, cerebrovascular disease and peripheral arterial occlusion (1 -9) although two studies, however, have failed to confirm these results (11, 12) . Lp(a) serum levels are quantified routinely with different analytical methods.
Electroimmunodiflusion (EID) is often referred to as the "standard" method to measure Lp(a) (15, 16) and has been used to investigate Lp(a) in many studies. It is a simple and robust method, which is on the one hand not sensitive enough to detect low levels of Lp(a) and on the other hand not suitable for measuring large numbers of samples. Only 25 samples can be applied per gel and it takes two days until results are available. The nephelometric and turbidimetric assays can be completely automated using modern nephelometers but difficulties can arise with lipaemic or haemolytic sera (13) . Furthermore, Lp(a) with its inverse relation between particle size and serum concentration is not the most suitable analyte for these techniques. These problems do not occur in sandwich immunoassays using either enzyme linked or radiolabelled antibodies for detection. Immunoradiometric assays (IRMA) and immunoenzymometric assays (IEMA) show excellent sensitivity and specifity (16) (17) (18) (19) (20) . They are capable of assaying large numbers of samples. The use of radiolabelled substances, however, limits the suitability of such methods for routine laboratory application. Our data show, that Lp(a) has been stable for at least 3 weeks at 4 °C, -20 °C and -80 °C (tab. 4). The calibrators and controls have been stored for 2 years at -80 °C without any loss of immunoreactivity. This is in agreement with the experience of other investigators ((23) and Wood, personal communication). Therefore, we cannot support the experience of Craig et al. (27) as far as twosite immunometric assays are concerned. The effect of freezing and thawing has been described previously (28) .
The different immunoreactivity of the Lp(a) isoforms remains a problem in Lp(a) quantification. In our studies dilution experiments with samples containing different apolipoprotein(a) isoforms showed linear dilution curves irrespective of the apolipoprotein(a) isoform, when measured with our method. Thus, it can be concluded, that the TRIFMA measures Lp(a) independently of apolipoprotein(a) isoforms. This may be explained by the use of two polyclonal antibodies in this assay. Furthermore, dilution experiments after separating the triacylglycerolrich fraction of serum and measuring both fractions separately showed linear and parallel dilution curves in different Lp(a) concentration ranges irrespective of the serum fraction ( fig. 6 ). These data suggest, that the TRIFMA can also measure free apolipoprotein(a). This can, however not be proved exactly due to lack in availability of free apolipoprotein(a), although both antibodies are directed against apolipoprotein(a) and not Lp(a).
The assay described here offers some advantages over other methods for Lp(a) quantification. In contrast to a similar assay described recently (23), we used the biotin streptavidin system with europium labelled streptavidin for the detection of the second antibody. Jürgens et al. (23) labelled their polyclonal anti apolipoprotein B or anti Lp(a) antibodies directly with europium. However, this is expensive because of the high price of the europium labelling reagent. Biotinylation of the antibody and europium labelling of streptavidin reduces the cost, because biotin is cheap and every labelled streptavidin molecule can, at least in theory, react specifically with biotin.
Our method was not affected by triacylglycerols (tab. 2) or haemolysis (tab. 1). The interference of plasminogen was neglegible (s. results). The assay offers a wide measuring range and a lower detection limit, which is satisfactory for both clinical and research purposes. The accuracy and the easy and rapid performance make the method well suited for routine use.
Even if there is still some discussion about the clinical validity of Lp(a), this analyte is frequently measured. No "gold standard" exists for quantifying Lp(a). In this paper we describe a method, which exclusively makes use of commercially available reagents and which includes the biotin steptavidin system. Therefore this assay can be performed in many laboratories, e. g. with use of streptavidin-enzyme or -isoluminol labelling, reagents which are both commercially available.
We compared the TRIFMA (25) with an EIA and with the EID-method and found a good correlation with both methods ( figs. 2 and 3) . Differences, however, were seen at low and high concentrations of Lp(a). This can be explained by the superior ability of the TRIFMA to detect low and high Lp(a) levels. The Lp(a) assay described here has been successfully used as routine method for quantifying Lp(a) in our laboratory for more than 1 1 /2 years.
